Mesoblast Limited (ASX:MSB)
2.220
-0.070 (-3.06%)
Nov 7, 2025, 4:10 PM AEST
Mesoblast Revenue
In the fiscal year ending June 30, 2025, Mesoblast had annual revenue of $17.20M USD with 191.39% growth. Mesoblast had revenue of $14.04M in the half year ending June 30, 2025, with 244.25% growth.
Revenue
$17.20M
Revenue Growth
+191.39%
P/S Ratio
108.57
Revenue / Employee
$212.32K
Employees
81
Market Cap
2.85B AUD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 17.20M | 11.30M | 191.39% |
| Jun 30, 2024 | 5.90M | -1.60M | -21.32% |
| Jun 30, 2023 | 7.50M | -2.71M | -26.54% |
| Jun 30, 2022 | 10.21M | 2.78M | 37.36% |
| Jun 30, 2021 | 7.43M | -24.72M | -76.88% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 23.73B |
| Ramsay Health Care | 17.79B |
| Sonic Healthcare | 9.65B |
| Ansell | 3.06B |
| Cochlear | 2.34B |
| Regis Healthcare | 1.16B |
| Telix Pharmaceuticals | 1.01B |
| Neuren Pharmaceuticals | 218.86M |
Mesoblast News
- 2 days ago - Mesoblast Breaks Below 200-Day Moving Average - Notable for MESO - Nasdaq
- 2 days ago - This Casino Stock Got Dealt A Good Hand - Benzinga
- 4 days ago - Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation - GlobeNewsWire
- 20 days ago - Mesoblast Q1 Revenue From Cell Therapy Products Surges - Nasdaq
- 20 days ago - Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch - GlobeNewsWire
- 4 weeks ago - Mesoblast: Back Pain And Heart Failure Remain Option Value, Not Base Case - Seeking Alpha
- 4 weeks ago - Mesoblast (MESO) Reports Strong Revenue Growth for Ryoncil Sales - GuruFocus
- 4 weeks ago - Mesoblast (MEOBF) Sees Significant Revenue Growth in Recent Quarter - GuruFocus